Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Get Rating) CEO Bobak R. Azamian sold 3,904 shares of Tarsus Pharmaceuticals stock in a transaction dated Wednesday, January 11th. The stock was sold at an average price of $15.11, for a total transaction of $58,989.44. Following the transaction, the chief executive officer now owns 1,124,613 shares of the company’s stock, valued at approximately $16,992,902.43. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.
Tarsus Pharmaceuticals Trading Down 0.2 %
Shares of TARS opened at $14.54 on Friday. The company has a debt-to-equity ratio of 0.10, a quick ratio of 16.40 and a current ratio of 16.40. The company has a 50-day moving average of $15.84 and a two-hundred day moving average of $16.05. Tarsus Pharmaceuticals, Inc. has a 12-month low of $10.80 and a 12-month high of $21.47.
Tarsus Pharmaceuticals (NASDAQ:TARS – Get Rating) last issued its quarterly earnings results on Wednesday, November 9th. The company reported ($0.84) EPS for the quarter, topping analysts’ consensus estimates of ($0.98) by $0.14. Tarsus Pharmaceuticals had a negative net margin of 324.99% and a negative return on equity of 34.24%. As a group, equities research analysts expect that Tarsus Pharmaceuticals, Inc. will post -2.61 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Tarsus Pharmaceuticals
Analysts Set New Price Targets
Separately, Oppenheimer cut their target price on shares of Tarsus Pharmaceuticals from $66.00 to $43.00 in a research report on Thursday, November 10th.
Tarsus Pharmaceuticals Company Profile
Tarsus Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.
- Get a free copy of the StockNews.com research report on Tarsus Pharmaceuticals (TARS)
- MarketBeat: Week in Review 01/09-01/13
- JPMorgan Chase Falls As Banks Brace For Recession
- Why is the Bed Bath & Beyond Stock Price up 261%?
- Roku Stock Price is Trending, Here’s Why
- Carvana Stock Rally, Here’s What You Need to Know
Receive News & Ratings for Tarsus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tarsus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.